SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

09 Nov 2022 Evaluate
Revenue reduced marginally to stand at Rs. 28289.60 millions during the quarter ended September 2022. The figure stood at Rs. 28701.70 millions during the year-ago period.The Total Profit for the quarter ended September 2022 of Rs. 1486.20 millions grew from Rs.-13291.20 millions Operating profit Margin for the quarter ended September 2022 improved to 3290.30% as compared to -13242.70% of corresponding quarter ended September 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 28289.60 28701.70 -1.44 55614.50 61842.90 -10.07 117716.70 110559.30 6.47
Other Income 153.70 746.80 -79.42 1006.80 1263.60 -20.32 2169.90 1290.90 68.09
PBIDT 3290.30 -13242.70 -124.85 6242.10 -3347.20 -286.49 4261.30 21731.50 -80.39
Interest 183.80 182.60 0.66 382.50 330.80 15.63 734.70 406.20 80.87
PBDT 3106.50 -13425.30 -123.14 5859.60 -3678.00 -259.31 3526.60 21325.30 -83.46
Depreciation 1377.60 1299.00 6.05 2681.10 2552.60 5.03 5141.90 5028.30 2.26
PBT 1728.90 -14724.30 -111.74 3178.50 -6230.60 -151.01 -1615.30 16297.00 -109.91
TAX 242.70 -1433.10 -116.94 520.50 601.90 -13.52 271.70 3710.80 -92.68
Deferred Tax -45.00 1760.30 -102.56 -56.60 1729.70 -103.27 -306.30 82.30 -472.17
PAT 1486.20 -13291.20 -111.18 2658.00 -6832.50 -138.90 -1887.00 12586.20 -114.99
Equity 909.40 908.10 0.14 909.40 908.10 0.14 909.00 907.40 0.18
PBIDTM(%) 11.63 -46.14 -125.21 11.22 -5.41 -307.37 3.62 19.66 -81.58

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×